A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
NCT00261430 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 650
Last updated 2011-05-17
Summary
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection over a two-year period of observation.
Conditions
Interventions
- BEHAVIORAL
-
GAIN Acceptance Approach
Sponsors & Collaborators
-
Janssen, LP
lead INDUSTRY
Principal Investigators
-
Janssen, LP Clinical Trial · Janssen, LP
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Completion
- 2004-10-31
More Related Trials
-
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00210691 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
NCT00236548 ·Status: COMPLETED ·Phase: PHASE3
-
Determining the Effects of Risperdal Consta in Patients With Psychotic Disorders and Incomplete Adherence
NCT00215579 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis
NCT00246259 ·Status: COMPLETED ·Phase: PHASE4
-
An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone
NCT00774085 ·Status: COMPLETED
-
A Study of the Efficacy and Safety of Long-acting Injectable Risperidone and Risperidone Tablets in Patients With Schizophrenia
NCT00240708 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder
NCT00297388 ·Status: COMPLETED ·Phase: PHASE3
-
An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia
NCT01894984 ·Status: TERMINATED
-
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
NCT00246285 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication
NCT00256997 ·Status: TERMINATED ·Phase: PHASE4
-
Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia
NCT00330551 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Efficacy and Safety of Risperidone Injections Given Once a Month to Adults With Schizophrenia or Schizoaffective Disorder
NCT00236353 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
NCT00132314 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Effectiveness of Risperdal® Consta® Compared to Abilify® Over a Two-year Period in Patients With Schizophrenia
NCT00299702 ·Status: COMPLETED ·Phase: PHASE4
-
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
NCT00249223 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone
NCT00246272 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
NCT00216528 ·Status: COMPLETED ·Phase: PHASE4
-
High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone
NCT00539071 ·Status: COMPLETED ·Phase: PHASE4
-
Long-acting Injectable Risperidone in Patients With Schizophrenia After an Acute Episode
NCT00216671 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder
NCT00992407 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
NCT00269919 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
NCT00216632 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia
NCT00589914 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
NCT00249132 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
NCT00236457 ·Status: COMPLETED ·Phase: PHASE3